Gastro Education 2018
Journal of Clinical Gastroenterology and Hepatology
ISSN: 2575-7733
Page 23
September 06-07, 2018
London, UK
14
th
International Conference on
Gastro Education
I
n the United States of America, colorectal cancer is the fourth
commonest type of cancer and the second leading cause
of cancer-related mortality. Colonoscopy is the first line to
prevent and treat colorectal cancer. Colon and rectal cancer
survival depend largely on the disease stage. Generally, the
earlier the disease is diagnosed, the longer the survival. The
5-year survival rate for patients with early disease (limited to
the intestinal mucosa) is 90%, that for regional disease (with
lymph node involvement) is 68%, and that for metastatic
disease is only 10%. Reduction of CRC incidence and mortality
is the most relevant and important outcome for those who
perform colonoscopy; thus, evaluation of this goal is essential.
Risk of interval cancer is another outcome parameter. A
high-quality colonoscopy decreases the chance of missing
or misdiagnosing existing lesions, and recommendations for
screening are made under these assumptions. In this context,
measuring quality of care in ways related to significant patient
outcomes is a widely shared goal, and, among them the
adenoma detection rate (ADR). The adenoma detection rate
(ADR), in as much as it has been tied both to interval cancer
occurrence and to colon cancer mortality. Currently, ADR has
been gaining more and more international recognition as a
quality indicator ADR is the only factor that correlates with
the diagnosis of interval cancer; a higher ADR is associated
with a lower incidence of interval cancer. The ADR is the
percentage of colorectal adenomas histologically proven
by screening colonoscopies performed by a physician or a
service. Currently, ASGE recommends an ADR of 20% or more
for female patients and 30% for male patients; however, there
is a lack of data regarding the validation of this goal. In this
view, the systematic review about this topic is very important. I
intend to speak about this topic.
Biography
Michele de Lemos Bonotto pursued her Master’s Degree in Medicine at Lis-
bon University, Portugal (2017) and Health Science University from Porto
Alegre, Brazil (2017). She graduated in Gastroenterology from the same
university (2014) and is an Endoscopist Specialist at Brazilian Society of Di-
gestive Endoscopy (2015). She is currently working at endoscopy center of
Santa Casa Hospital and Moinhos Hospital respectively.
mime.b@icloud.comColorectal cancer is the third commonest cancer in men and
the second in women worldwide
Michele de Lemos Bonotto
1,2,3
1
Federal University of Health Sciences of Porto Alegre, Brazil
2
Santa Casa de Misericordia, Brazil
3
Hospital Moinhos de Vento Brazil
Michele de Lemos Bonotto, J Clin Gastroenterol Hepatol 2018, Volume 2
DOI: 10.21767/2575-7733-C2-005




